Myrio

Myrio Therapeutics is an Australian biotechnology company specializing in the discovery and development of antibodies against intracellular targets. The company utilizes a proprietary yeast-display platform to generate high-affinity, human single-chain variable fragments (scFvs) that recognize peptide-MHC complexes. This technology enables the targeting of the "undruggable" proteome, effectively reaching proteins inside the cell that are typically inaccessible to traditional antibody therapies. Myrio's primary focus is on oncology, where it aims to develop precision therapies for solid tumors by leveraging the specificity of T-cell receptor-like antibodies. The company was spun out of the Peter MacCallum Cancer Centre and is backed by leading life science investors.